Diabetes, Vol 38, Issue 7 938-941, Copyright © 1989 by American Diabetes Association

ARTICLES

Anti-sympathetic nervous system autoantibodies. Diminished catecholamines with orthostasis

FM Brown, SJ Brink, R Freeman and SL Rabinowe
Immunology Section, Joslin Diabetes Center, Boston, MA 02215.

The etiology of autonomic neuropathy in insulin-dependent diabetes mellitus (IDDM) is unknown. Previous studies have noted the presence of anti-adrenal medullary antibodies in IDDM. Recently, we have also demonstrated the presence of anti-sympathetic ganglia antibodies in IDDM. We initiated a study to evaluate whether subjects with complement-fixing anti-adrenal medullary (CF-ADM) and anti-sympathetic ganglia (CF-SG) antibodies have a decreased catecholamine response to change in posture. Seven IDDM subjects aged 19-41 yr with duration of disease 5-21 yr at the time of the posture study were evaluated. Serums collected longitudinally were evaluated for the presence of CF-ADM and CF-SG antibodies. Three IDDM subjects were CF-ADM- and CF-SG- at all testing intervals (Ab- group). Four IDDM subjects were CF-ADM+ and/or CF-SG+ on at least one testing date (Ab+ group). Baseline mean norepinephrine and epinephrine levels were not significantly different in Ab+ and Ab- subjects. Norepinephrine levels 5 min after standing were mean +/- SD 227 +/- 16 and 419 +/- 48 pg/ml for Ab+ and Ab- subjects, respectively (P less than .03). The means of the 5-min minus basal norepinephrine levels were 88 +/- 42 (Ab+) and 207 +/- 26 (Ab-) pg/ml (P less than .03). Mean epinephrine levels after 5 min of standing were 35 +/- 16 (Ab+) and 101 +/- 44 (Ab-) pg/ml (P less than .03). The means of the 5-min minus basal epinephrine levels were 1 +/- 5 (Ab+) and 43 +/- 38 (Ab-) pg/ml (P less than .03).(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. I. Vinik, D. Anandacoomaraswamy, and J. Ullal Antibodies to Neuronal Structures: Innocent bystanders or neurotoxins? Diabetes Care, August 1, 2005; 28(8): 2067 - 2072. [Full Text] [PDF]

				K. R. Sharma, J. Cross, D. R. Ayyar, A. Martinez-Arizala, and W. G. Bradley Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy Arch Neurol, May 1, 2002; 59(5): 751 - 757. [Abstract] [Full Text] [PDF]

				K. R. Sharma, J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley Demyelinating Neuropathy in Diabetes Mellitus Arch Neurol, May 1, 2002; 59(5): 758 - 765. [Abstract] [Full Text] [PDF]

				S. S Jaradeh, T. E Prieto, and L. J Lobeck Progressive polyradiculoneuropathy in diabetes: correlation of variables and clinical outcome after immunotherapy J. Neurol. Neurosurg. Psychiatry, November 1, 1999; 67(5): 607 - 612. [Abstract] [Full Text]

				W. H. Hoffman, J. E. Carroll, G. Y. Perry, P. L. Hartlage, S. J. Kaminer, N. C. Flowers, S. J. Oh, and D. R. Kelly Giant Axonal Neuropathy in a Child With Insulin-Dependent Diabetes Mellitus J Child Neurol, May 1, 1995; 10(3): 250 - 253. [PDF]